We evaluated the effects of a selective serotonin reuptake inhibitor, paroxetine, on treating tinnitus.Tinnitus patients stratified for the presence of depression and anxiety were studied retrospectively. Fifty-six patients were observed for more than 6 months. They were initially treated with paroxetine only at a dose of 10 mg/day for 2–4 weeks; thereafter, the dose was increased to 20 mg/day. Tinnitus distress was evaluated with the Tinnitus Handicap Inventory (THI) and with visual analog scales (VASs) for tinnitus loudness and annoyance. Depression and anxiety were measured with the Self-Rating Depression Scale (SDS) and the trait section of the State-Trait Anxiety Inventory (STAI). The patients were grouped according to their SDS and STAI scores, and each variable was compared at baseline and the 6-month follow-up. Changes among these variables were also examined to determine whether reduced tinnitus distress was related to the improvement of depression or anxiety. Patients with both depression and anxiety showed better results (decrease in THI, VASs, SDS and STAI scores) than patients with anxiety alone, or patients without depression and anxiety. In patients with depression and anxiety, changes in tinnitus variables and changes in depression and anxiety scores were strongly correlated. In other patients, however, changes in tinnitus variables and changes in depression and anxiety scores were not correlated. These results suggest that paroxetine is effective in treating distressed tinnitus patients with depression and anxiety by reducing their tinnitus severity as well as their depression and anxiety.

1.
Baldo P, Doree C, Lazzarini R, Molin P, McFerran DJ: Antidepressants for patients with tinnitus. Cochrane Database Syst Rev 2006;4:CD003853.
2.
Coles RR: Epidemiology of tinnitus: (1) prevalence. J Laryngol Otol Suppl 1984;9:7–15.
3.
Dobie RA: A review of randomized clinical trials in tinnitus. Laryngoscope 1999;109:1202–1211.
4.
Dobie RA: Depression and tinnitus. Otolaryngol Clin North Am 2003;36:383–388.
5.
Dobie RA, Sakai CS, Sullivan MD, Katon WJ, Russo J: Antidepressant treatment of tinnitus patients: report of a randomized clinical trial and clinical prediction of benefit. Am J Otol 1993;14:18–23.
6.
Folmer RL, Griest SE, Martin WH: Chronic tinnitus as phantom auditory pain. Otolaryngol Head Neck Surg 2001;124:394–400.
7.
Folmer RL, Griest SE, Meikle MB, Martin WH: Tinnitus severity, loudness, and depression. Otolaryngol Head Neck Surg 1999;121:48–51.
8.
Halford JB, Anderson SD: Anxiety and depression in tinnitus sufferers. J Psychosom Res 1991;35:383–390.
9.
Heller AJ: Classification and epidemiology of tinnitus. Otolaryngol Clin North Am 2003;36:239–248.
10.
Newman CW, Jacobson GP, Spitzer JB: Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg 1996;122:143–148.
11.
Newman CW, Sandridge SA, Jacobson GP: Psychometric adequacy of the Tinnitus Handicap Inventory (THI) for evaluating treatment outcome. J Am Acad Audiol 1998;9:153–160.
12.
Robinson SK, Viirre ES, Bailey KA, Gerke MA, Harris JP, Stein MB: Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med 2005;67:981–988.
13.
Robinson SK, Viirre ES, Stein MB: Antidepressant therapy in tinnitus. Hear Res 2007;226:221–231.
14.
Simpson JJ, Davies WE: A review of evidence in support of a role for 5-HT in the perception of tinnitus. Hear Res 2000;145:1–7.
15.
Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA: Manual for the State-Trait Anxiety Inventory (Form Y). Palo Alto, Consulting Psychologists Press, 1983.
16.
Sullivan M, Katon W, Russo J, Dobie R, Sakai C: A randomized trial of nortriptyline for severe chronic tinnitus: effects on depression, disability, and tinnitus symptoms. Arch Intern Med 1993;153:2251–2259.
17.
Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL: Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 2002;62:655–703.
18.
Zoger S, Svedlund J, Holgers KM: Relationship between tinnitus severity and psychiatric disorders. Psychosomatics 2006;47:282–288.
19.
Zung WW: A self-rating depression scale. Arch Gen Psychiatry 1965;12:63–70.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.